Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RA<sup>+</sup> T-cell depleted donor lymphocyte infusion.

Geroscience · 2026 · PMC13356011 · PMID 41526596

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0588

boldest claim

The sentences

showed a trendp = 0.058so close (0.05 < p ≤ 0.1)

However, CD45RA + TCD DLI showed a trend toward improved 1-year COVID-19–free survival ( p = 0.058) and significantly better survival among HSCT recipients ( p = 0.0362).

also in 53,322 other papers

did not reach statistical significancep = 0.0588so close (0.05 < p ≤ 0.1)

Using the log-rank test, 1-year OS did not differ between the two groups ( p = 0.8907); however, 1-year COVID-free survival was higher in the CD45RA+ TCD DLI cohort, although this difference did not reach statistical significance ( p = 0.0588) (Fig. 1 A-B).

also in 111,027 other papers

a decreasing trendno p-value reported

Between weeks 2 and 4, the groups showed no difference, with a decreasing trend in CD3 + T-cell percentage in the CD45RA + TCD DLI group from weeks 5–8. to 8.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RA&lt;sup&gt;+&lt;/sup&gt; T-cell depleted donor lymphocyte infusion.

The sentences

Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: Comparison of IFN-γ virus-specific T-cell therapy and CD45RA<sup>+</sup> T-cell depleted donor lymphocyte infusion.